These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16138589)

  • 1. [Instructions for the combination of PDE5 inhibitors with alpha-blockers].
    Liu JH; Wang T
    Zhonghua Nan Ke Xue; 2005 Aug; 11(8):635-9. PubMed ID: 16138589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia.
    Ng CF; Wong A; Cheng CW; Chan ES; Wong HM; Hou SM
    J Urol; 2008 Sep; 180(3):1042-6. PubMed ID: 18639296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Advancements in Benign Prostatic Hyperplasia Treatments.
    Ganesan V; Agarwal D
    Curr Urol Rep; 2024 May; 25(5):93-98. PubMed ID: 38448685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatments for benign prostatic hyperplasia and sexual function.
    Giuliano F
    BJU Int; 2008 Nov; 102 Suppl 2():8-12. PubMed ID: 19032604
    [No Abstract]   [Full Text] [Related]  

  • 7. [Erectile disfunction and benign prostatic hyperplasia - causal relation or coincidence?].
    Gasser T
    Ther Umsch; 2010 Mar; 67(3):145-7. PubMed ID: 20235043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phosphodiesterase inhibitors: effectiveness and new applications].
    van Driel MF
    Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA
    Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or α-adrenoceptor antagonist?
    Wyllie MG
    BJU Int; 2012 Apr; 109(7):965-6. PubMed ID: 22373009
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
    Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
    Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Another year, another AUA.
    Wyllie MG
    BJU Int; 2006 May; 97(5):1119-20. PubMed ID: 16643502
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis].
    Jin Z; Xin ZC
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 43(4):632-5. PubMed ID: 21844982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One drug fits all.
    Wyllie MG
    BJU Int; 2005 Sep; 96(4):677-8. PubMed ID: 16104930
    [No Abstract]   [Full Text] [Related]  

  • 15. Uropharmacology: current and future strategies in the treatment of erectile dysfunction and benign prostate hyperplasia.
    Engl T; Beecken WD; Wolfram M; Jonas D; Blaheta R
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):527-33. PubMed ID: 15516021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New treatments in erectile dysfunction].
    Palma-Aguirre JA
    Gac Med Mex; 1999; 135(6):663-8. PubMed ID: 10605271
    [No Abstract]   [Full Text] [Related]  

  • 17. [Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].
    Caviezel A; Iselin CE
    Rev Med Suisse; 2011 Dec; 7(320):2394-7. PubMed ID: 22232868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
    Liguori G; Trombetta C; De Giorgi G; Pomara G; Maio G; Vecchio D; Ocello G; Ollandini G; Bucci S; Belgrano E
    J Sex Med; 2009 Feb; 6(2):544-52. PubMed ID: 19138360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
    Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
    Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.